Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 29Urinary Bladder Neoplasms 26Carcinoma, Renal Cell 22Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Ureteral Neoplasms 5Prostatic Neoplasms 5Ovarian Neoplasms 5Melanoma 5Carcinoma, Merkel Cell 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Penile Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Turcot syndrome 1Testicular Neoplasms 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 13Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5dodecyl maltoside 5Radiotherapy 5Cystoscopy 5apaziquone 4ALT-803 4tislelizumab 35-aminolevulinic acid hexyl ester 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 2Administration, Intravesical 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × avelumab × Genitourinary × Clear all
NCT03498196 2020-08-24

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Baylor College of Medicine

Phase 1/2 Terminated
1 enrolled 10 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03950362 2019-05-16

PREVERT

Institut Paoli-Calmettes

Phase 2 Unknown
67 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡